期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

抗动脉粥样硬化药物研究进展 被引量：1

Progress in Research on Antiatherosclerosis Drugs
下载PDF
导出
摘要 动脉粥样硬化是许多心血管疾病的主要病理基础之一。根据作用机制的不同 ,分类概述用于动脉粥样硬化治疗的ACAT抑制剂、胆汁酸吸收抑制剂、胆固醇合成抑制剂、抗氧化剂、PPAR激动剂、糜酶抑制剂等药物的研究近况。 Atherosclerosis plays a significiant role in the pathogenesis of many cardiovascular diseases. According to the different acting mechanisms,several antiatherosclerosis drugs such as ACAT inhibitor, bile acid absorbtion inhibitor, cholesterol synthesis inhibitor, antioxidant, PPAR agonist, chymase inhibitor and so on,were described in this review.
作者 闵真立 姜凤超
机构地区 华中科技大学同济医学院药学院
出处 《药学进展》 CAS 2004年第3期108-116,共9页 Progress in Pharmaceutical Sciences
关键词 动脉粥样硬化 药物研究 心血管疾病 ACAT抑制剂 抗氧化剂 PPAR激动剂 Antiatherosclerosis, ACAT inhibitor, Antioxidant, PPAR agonist
分类号 R972 [医药卫生—药品]
  • 相关文献

参考文献44

  • 1[1]Ross R. Atherosclerosis-an inflammatory disease[J]. N Engl J Med,1999,340:115-126.
  • 2[2]Koenig W. Inflammation and coronary heart disease:an overview[J]. Cardiol Rev,2001,9(1):31-35.
  • 3[3]Sakashita N, Miyazaki A, Takeya M, et al. Localization of human acyl-coenzyme A:cholesterol acyltransferase-1 (ACAT-1) in macrophages and in variens tissues[J]. Am J Pathol, 2000, 156(1):227-236.
  • 4[4]Chang C, Sakashita N, Ornvold K, et al.Immunological quantitation and localization of ACAT-1 and ACAT-2 in human liver and small intestine[J].J Biol Chem, 2000, 275(36):28083-28092.
  • 5[5]Lu X, Lin S, Chang C, et al. Mutant acyl-coenzymeA,cholesterol acyltransferase1 devoid of cysteine residices remains catalytically active[J]. J Biol Chem,2002, 277(1): 711-718.
  • 6[6]Gotto A M, Jr. Hypercholesterolemia:looking forward[J].Clin Cardiol, 2003, 26(suppl, 1):21-28.
  • 7[7]Ohishi K, Aiyama R, Hatano H, et al. Structure-Activity Relationships of N-(3,5-dimethoxy-4-n-octyloxycimnamoyl)-N'-(3,4-dimethylphenyl)piperazine and analogues as inhibitors of acyl-CoA:cholesterol-acyltransferase[J]. Chem Pharm Bull, 2001, 49(7):830-839.
  • 8[8]Tauchi Y, Yoshimi A, Shirahase H, et al.Inhibitory effect of acyl-CoA:Cholesterol acyltransferase inhibitor-lower density lipoprotein complex on experimental atherosclerosis[J]. Biol Pharm Bull, 2003, 26(1):73-78.
  • 9[9]Booker M L. S-8921[J]. Curr Opin Investig Drugs, 2001, 2(3):393-395.
  • 10[10]West K L, Ramjiganesh T, Roy S, et al. SC-435, an ileal apical sodium-codependent bile acid transporter inhibitor acters hepatic cholesterol metabolism and lowers plasma low-density lipoprotein-cholesterol concentrations in Guinea Pigs[J]. J Pharmacol Exp Ther, 2002, 303(1):293-299.

同被引文献11

引证文献1

二级引证文献3

药学进展
2004年 第3期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部